Send to

Choose Destination
Int J Cancer. 2019 Aug 1;145(3):842-856. doi: 10.1002/ijc.32185. Epub 2019 Feb 19.

Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.

Sun W1,2,3, Xu X1,2,3, Jiang Y1,2,3, Jin X1,2,3, Zhou P4, Liu Y1,2,3, Guo Y1,2,3, Ma D1,2,3, Zuo W1,2,3, Huang S3,5, He X3,5, Shao Z1,2,3,6.

Author information

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Breast Surgery, The Third Hospital of Nanchang, Nanchang, Jiangxi Province, China.
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Institutes of Biomedical Sciences, Fudan University, Shanghai, China.


Luminal breast cancer (BC) has a sustained risk of late disease recurrence and death. Considerable numbers of patients suffer from antiendocrine therapy resistance. Here, we identified a novel lncRNA whose expression is high in breast cancer and especially higher in luminal breast cancer, dubbed LOL (lncRNA of luminal), that acts as a natural sponge for let-7 microRNAs to regulate tumor growth and tamoxifen resistance. LOL overexpression in parental MCF-7 cells exhibited a proliferative advantage in the addition of tamoxifen than negative control. Knocking down LOL in TamR MCF-7 cells, recovered the sensitivity of cells to tamoxifen. Strikingly, we demonstrated that LOL is transcribed from a genomic locus of an enhancer to maintain its high expression in luminal BC and that it is extremely sensitive to enhancer-regulating factors, such as ZMYND8 and BRD4. Estrogen deprivation or ERα signaling pathway blockage can further stimulate LOL expression, which can promote tumor progression. Clinical analysis of 374 luminal breast cancer samples indicated that LOL is an independent prognostic factor for poor survival in luminal BC. In conclusion, targeting LOL using preclinical/clinical drugs, such as BRD4 inhibitors, may represent a promising approach to inhibit luminal breast cancer progression and tamoxifen resistance.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center